These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1002 related articles for article (PubMed ID: 16895934)

  • 1. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India.
    Gaind R; Paglietti B; Murgia M; Dawar R; Uzzau S; Cappuccinelli P; Deb M; Aggarwal P; Rubino S
    J Antimicrob Chemother; 2006 Dec; 58(6):1139-44. PubMed ID: 17071955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian Salmonella serovars and their mutants selected during the determination of mutant prevention concentrations.
    Kehrenberg C; de Jong A; Friederichs S; Cloeckaert A; Schwarz S
    J Antimicrob Chemother; 2007 May; 59(5):886-92. PubMed ID: 17369276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of mutations in the gyrA gene in fluoroquinolone resistance Salmonella enterica serotypes typhi and paratyphi A isolated from the Infectious Diseases Hospital, Kuwait.
    Dimitrov T; Dashti AA; Albaksami O; Jadaon MM
    J Clin Pathol; 2010 Jan; 63(1):83-7. PubMed ID: 19889623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals.
    Sáenz Y; Zarazaga M; Briñas L; Ruiz-Larrea F; Torres C
    J Antimicrob Chemother; 2003 Apr; 51(4):1001-5. PubMed ID: 12654733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel restriction enzyme SSiI for the detection of mutation in GyrA gene of Salmonella enterica serovar Typhi.
    Agrawal P; Kapila K; Kumar S; Ghosh AN; Maurya AK
    Indian J Pathol Microbiol; 2010; 53(3):509-12. PubMed ID: 20699513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fluoroquinolone resistance mutations in topoisomerase genes of Salmonella typhimurium isolates].
    Guo Y; Pei X; Liu X
    Wei Sheng Yan Jiu; 2004 Sep; 33(5):591-4. PubMed ID: 15612489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).
    Davies TA; Yee YC; Goldschmidt R; Bush K; Sahm DF; Evangelista A
    J Antimicrob Chemother; 2006 Mar; 57(3):437-42. PubMed ID: 16431861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence and properties of fluoroquinolone resistant Salmonella enterica serovar Typhi strains isolated from Nepal in 2002 and 2003.
    Nobthai P; Serichantalergs O; Wongstitwilairoong B; Srijan A; Bodhidatta L; Malla S; Mason CJ
    Southeast Asian J Trop Med Public Health; 2010 Nov; 41(6):1416-22. PubMed ID: 21329318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid detection of gyrA and parC mutations in quinolone-resistant Salmonella enterica using Pyrosequencing technology.
    Hopkins KL; Arnold C; Threlfall EJ
    J Microbiol Methods; 2007 Jan; 68(1):163-71. PubMed ID: 16934351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
    Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
    J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
    Lee JK; Lee YS; Park YK; Kim BS
    Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Pefloxacin for detection of fluoroquinolone (FQ) resistance among
    Inayath SB; Broor S; Gupta R; Agarwal P; Majumder S; Anveshi AK; Gaind R
    J Med Microbiol; 2021 Aug; 70(8):. PubMed ID: 34356003
    [No Abstract]   [Full Text] [Related]  

  • 19. [Analysis of point mutations in the ygeD, gyrA and parC genes in fluoroquinolones resistant clinical isolates of Chlamydia trachomatis].
    Misiurina OIu; Shipitsina EV; Finashutina IuP; Lazarev VN; Akopian TA; Savicheva AM; Govorun VM
    Mol Gen Mikrobiol Virusol; 2004; (3):3-7. PubMed ID: 15354934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.